Clinical Trial Update: To Compare Efficacy and Safety of CMAB007 and Xolair® in Patients With Chronic Spontaneous Urticaria [Phase 3]

View source ↗

Summary

Phase 3 study comparing CMAB007 to Xolair (omalizumab) for chronic spontaneous urticaria is currently recruiting. The trial aims to evaluate comparative efficac…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spontaneous Urticaria

Drugs mentioned

• CMAB007 (omalizumab)
• Xolair (omalizumab)

Snippet

Sponsor: Taizhou Mabtech Pharmaceutical Co.,Ltd | Conditions: Chronic Spontaneous Urticaria | Phase 3 | Status: RECRUITING